Andere talen Luye Pharma Group Ltd.

Aandelen

2186

BMG570071099

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:35 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,61 ^HKD	-0,38%		-4,74%	-30,03%

27/03	Luye Pharma Group Ltd. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
07/03	Luye Pharma Group kondigt de lancering aan van zijn innovatieve geneesmiddel Zepzelca® (lurbinectedine) voor de behandeling van SCLC in zowel Hongkong als Macau	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	07/03
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	04/03
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	04/03
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02/02
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	01/02
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	13/12
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	13/12
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12/12
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	12/12
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12/12
Luye Pharma Group Ltd. Announces Board Changes	06/12
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05/12
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	04/12
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	04/12
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	01/11
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease	01/11
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	31-10-23
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	09-10-23
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	09-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Luye Pharma Group Ltd.

Aandelen

2186

BMG570071099

Andere talen

Filters